Market Overview

Vetr Community Upgrades Teva Pharmaceuticals


The Vetr community last Friday upgraded Teva Pharmaceuticals Ltd. (ADR) ADR (NYSE: TEVA) from 4 stars (Buy) to 4.5 stars (Strong Buy). Crowd confidence was very bullish, with 82.6 percent of the Vetr community giving the stock a buy rating and 17.4 percent a Sell.

See how crowdsourced ratings could help you time the market

This upgrade came despite news that Teva failed to meet endpoints in a late-stage asthma study, though there was little price movement at market close. The Vetr crowd remained bullish with a target price of $23.94 compared to the current share price of $20.98, implying a 13.93 percent upside.


Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General

Latest Ratings

WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at